anticoagulant

Acenocoumarol - Betrixaban - Phenindione      

Select            
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

acute coronary syndrome

apixaban
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%
coumadin
ASPECT-2 (coumadin+asp vs asp), 2002     coumadincontrol (on top of aspirin)suggesting135%
ASPECT-2 (coumadin vs aspirin), 2002   coumadinaspirinsuggesting3%
dabigatran
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009    NCTotamixabanunfractionated heparinLow risk of bias suggesting
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting 243%-33%
ATLAS ACS-TIMI 46 (2.5mg), 2009      NCTrivaroxaban 2.5mgplaceboLow risk of bias negative276%
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting 333%-58%
ATLAS ACS-TIMI 46 (5mg), 2009      NCTrivaroxaban 5mgplaceboLow risk of bias negative 1664%
warfarin
ATACS (pilot study) (warfarin vs control), 1990     warfarincontrol (on top of aspirin)negative-14%
ATACS, 1994   warfarincontrol (on top of aspirin)negative+Infini%
CARS, 1997     warfarincontrol (on top of aspirin)negative29%
OASIS Pilot (phase 1), 1998     warfarincontrol (on top of aspirin)negative+Infini%
OASIS Pilot (phase 2), 1998     warfarincontrol (on top of aspirin)negative102%
OASIS-2 Warfarin Substudy, 2001     warfarincontrol (on top of aspirin)negative 98%
APRICOT-2, 2002     warfarincontrol (on top of aspirin)negative3%
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%
WARIS, 2002     warfarincontrol (on top of aspirin)suggesting 249%
LoWASA, 2004     warfarincontrol (on top of aspirin)negative 104%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative150%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias negative+Infini%
Huyhn, 2001     warfarinplacebo (on top of aspirin)Low risk of bias negative+Infini%
ATACS (pilot study) warfarin vs aspirin, 1990     warfarinaspirinnegative
ximelagatran
ESTEEM, 2003   ximelagatranplaceboExploratory -

acute myocardial infarction

coumadin
ASPECT-2 (coumadin+ASA vs ASA), 2002     coumadincontrol (on top of aspirin)negative 126%-42%
ASPECT, 1994   coumadinplaceboLow risk of bias suggesting 285%-10%
ASPECT-2 (coumadin alone), 2002     coumadinaspirinsuggesting3%-72%
warfarin
APRICOT-2, 2002     warfarincontrol (on top of aspirin)suggesting3%+Infini%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative 150%-67%
WARIS, 1999   warfarincontrol (on top of aspirin)Low risk of bias -
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%2%
CARS (warafrin 3mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias suggesting9%-27%
LoWASA, 2004     warfarincontrol (on top of aspirin)Risk of bias suggesting 123%-5%
CARS (warfarin 1mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias negative 45%3%
WARIS II (warfarin+ASA), 2002     warfarincontrol (on top of aspirin)suggesting 232%-2%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias suggesting+Infini%-100%
WARIS II (warfarin alone), 2002     warfarinaspirinsuggesting 309%3%

cardiovascular prevention

dicoumarol
Apenstrom and Korsan-Bengtsen, 1964   dicoumarolno anticoagulant -
rivaroxaban
COMPASS (rivaroxaban alone), 2017    NCTrivaroxabanaspirinsecondary prevention -
COMPASS (rivaroxaban + aspirin), 2017      NCTrivaroxaban + aspirinaspirinsecondary preventionLow risk of bias - 8100%
wafarin
WARIS, 1990   warfarinplaceboLow risk of bias -
warfarin
Thrombosis Prevention trial (Warfarin), 1998        NCTwarfarinplaceboprimary preventionLow risk of bias suggesting -17%
Thrombosis Prevention trial (W plus A), 1998        NCTwarfarin + aspirinplaceboprimary preventionLow risk of bias suggesting -7%

coronary artery disease

dicoumarol
Apenstrom and Korsan-Bengtsen, 1964   dicoumarolno anticoagulant -
wafarin
WARIS, 1990   warfarinplaceboLow risk of bias -

heart failure

rivaroxaban
COMMANDER HF, 2018      NCTrivaroxabanplacebonegative-2%
warfarin
HELAS (warfarin vs placebo), 2006   warfarinplaceboLow risk of bias -
HELAS (warfarin vs aspirin), 2006   warfarinaspirinLow risk of bias -
WATCH (warfarin vs aspirin), 2009      NCTwarfarinaspirinsuggesting43%-5%

percutaneous coronary intervention

bivalirudin
REPLACE-2, 2003         bivalirudinheparin + GP2b3a inhibitorsLow risk of bias -
HORIZONS-AMI (Stone), 2008        NCTbivalirudinheparin + GP2b3a inhibitorsRisk of bias suggesting-39%-34%
ACUITY (Stone) (bivalirudin alone), 2006      NCTbivalirudinheparin + GP2b3a inhibitorsRisk of bias -
Kleiman, 2002     bivalirudin + eptifibatideheparin + GP2b3a inhibitorsExploratory -
ISAR-REACT 3, 2008    NCTbivalirudinUFHLow risk of bias -
REPLACE-1, 2004     bivalirudinUFHExploratory negative-100%
BAT (Bittl), 1995             bivalirudinUFHLow risk of bias suggesting-61%123%
ARMYDA BIVALVE   bivalirudinUFH -
NAPLES (Tavano), 2009     bivalirudinUFH plus tirofibanRisk of bias suggesting-75%
dalteparin
Natarajan (without antiGp2b3a), 2003   dalteparinUFH -
Natarajan (+ antiGp2b3a), 2003   dalteparinUFH + anti Gp2b3a -
enoxaparin
STEEPLE, 2006      NCTenoxaparinUFHRisk of bias -
Rabah, 1999     enoxaparinUFHExploratory negative
CRUISE, 2003     enoxaparinUFHExploratory negative
Galeote, 2001   enoxaparinUFHnegative
Dudek, 2000   enoxaparinUFHnegative
Dudek b (enox alone), 2000   enoxaparinUFH -
Drozd, 2001   enoxaparinUFHnegative
ATOLL, 2010   enoxaparinUFHRisk of bias -
Dubek b (+abciximal), 2001   enoxaparin+abciximabUFH -
reviparin
REDUCE, 1996     reviparinUFHLow risk of bias suggesting

peripheral vascular diseases

warfarin
Johnson, 2002   warfarincontrôle -
Sarac, 1998   warfarincontrôle -

post myocardial infarction

coumadin
ASPECT-2 (coumadin+ASA vs ASA), 2002     coumadincontrol (on top of aspirin)negative 126%-42%
ASPECT, 1994   coumadinplaceboLow risk of bias suggesting 285%-10%
ASPECT-2 (coumadin alone), 2002     coumadinaspirinsuggesting3%-72%
warfarin
APRICOT-2, 2002     warfarincontrol (on top of aspirin)suggesting3%+Infini%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative 150%-67%
WARIS, 1999   warfarincontrol (on top of aspirin)Low risk of bias -
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%2%
CARS (warafrin 3mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias suggesting9%-27%
LoWASA, 2004     warfarincontrol (on top of aspirin)Risk of bias suggesting 123%-5%
CARS (warfarin 1mg), 1997     warfarincontrol (on top of aspirin)Low risk of bias negative 45%3%
WARIS II (warfarin+ASA), 2002     warfarincontrol (on top of aspirin)suggesting 232%-2%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias suggesting+Infini%-100%
WARIS II (warfarin alone), 2002     warfarinaspirinsuggesting 309%3%

post stroke

dicoumarol
Howard, 1963   dicoumarolplacebonegative
Nat-Coop, 1962   dicoumarolplacebosuggesting
phenindione
Enger, 1965   phenindioneplacebonegative
Thygesen, 1964   phenindioneplacebonegative
rivaroxaban
NAVIGATE ESUS, 2018      NCTrivaroxabanaspirin -
warfarin
SWAT, 1998   warfarinaspirinnegative

thrombosis prevention

acenocoumarol
Hamulyak, 1994   AcenocoumarolNadroparinnegative60%
Samama, 2001     AcenocoumarolReviparinnegative 289%+Infini%
van Geloven, 1977   Acenocoumarolunfractionated heparinLow risk of bias -
apixaban